August 24, 2023 SANTA CLARA, Calif.--(BUSINESS WIRE)--Exo (pronounced “echo”), a pioneering medical imaging software and devices company, today announced the appointment of Kurt Hammond to Chief Commercial Officer. With more than three decades of experience scaling healthcare software brands, Hammond will be responsible for developing and executing the sales, marketing, partnerships and customer success strategies to drive the commercialization of Exo’s fully integrated ultrasound ecosystem.

Hammond most recently served as Chief Growth Officer at eMed Digital Healthcare, where he oversaw sales, customer success, product management, marketing and partnership development functions for a first-of-its-kind point-of-care diagnostic lab platform. Prior to eMed Digital Healthcare, he led six healthcare startups, including Halo Health and Merge Healthcare, to successful exits and has been involved in more than 20 mergers and acquisitions in the healthcare market. After Merge Healthcare was acquired by IBM in 2015, Hammond was named VP of Global Imaging Sales for IBM Watson Health, eventually being promoted to Global VP of Partnerships and Business Development.

“With deep-rooted expertise in healthcare IT, SaaS and artificial intelligence, Kurt is the ideal leader to usher Exo into our next phase of growth. He shares our vision of bringing healthcare outside the constraints of hospital walls and uniquely understands the solutions required to make that a reality,” said Sandeep Akkaraju, Co-founder and CEO of Exo. “As Exo expands its medical imaging ecosystem, Kurt’s experience leading market-altering health tech companies will be core to our success.”

Hammond’s appointment as Chief Commercial Officer comes at a pivotal time in Exo’s trajectory in delivering simple and accessible medical imaging to all. The company has developed an end-to-end ultrasound ecosystem to provide caregivers with immediate medical answers at the point of care to improve patient outcomes. That includes launching its award-winning Exo Works™ point-of-care ultrasound (POCUS) workflow solution last year, which streamlines documentation, billing and quality assurance in one platform. Exo has also acquired FDA-cleared AI capabilities and will be commercializing a revolutionary new handheld ultrasound. Built on Exo’s proprietary ultrasound technology, this pocket-sized ultrasound device delivers high-performance imaging at a fraction of the cost of cart-based systems.

More People on the Move